%0 Journal Article
%T LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK¨CMfn2 signaling pathway
%A Chang Lu
%A Jie Song
%A Wei Zhao
%A Xue Shao
%J Archive of "Cancer Cell International".
%D 2019
%R 10.1186/s12935-019-0778-1
%X LATS2 overexpression increases sorafenib-mediated cell death in HepG2 liver cancer cells in vitro. a, b Different doses of sorafenib was added into the medium of HepG2 cells and then the expression of LATS2 was determined via western blotting. c RNA was isolated from HepG2 cells after exposure to sorafenib and then the transcription of LATS2 was evaluated via qPCR. d Cellular viability was measured via MTT assay. Different doses of sorafenib was added into the medium of HepG2 cells. e, f Adenovirus transfection was used to perform the overexpression assay of LATS2 in the presence of sorafenib treatment. The overexpression efficiency was confirmed via western blotting. g LDH release assay was used to evaluate cell death in response to sorafenib treatment and/or LATS2 overexpression. h Caspase-3 activity of HepG2 cells. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. i, j TUNEL assay for apoptotic cells. The number of apoptotic cells was recorded. Adenovirus-loaded LATS2 was transfected into HepG2 cells in the presence of sorafenib. *p£¿<£¿0.05 vs. control group; #p£¿<£¿0.05 vs. Sorafenib£¿+£¿Ad-cont grou
%K HCC
%K Mitophagy
%K Sorafenib
%K AMPK pathway
%K LATS2
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423758/